Case Comprehensive Cancer Center
Cleveland, Ohio
Gary Schwartz, MD, is the Director of the Case Comprehensive Cancer Center (Case CCC). Formerly Chief of Hematology and Oncology at Columbia University and Deputy Director of the Herbert Irving Comprehensive Cancer Center, his vision is to establish highly innovative, transformative clinical translational research programs in the field of cancer therapy. His post at Case CCC follows 23 years of extensive work in early drug development with bench-top to bedside research in gastrointestinal cancers, melanoma, and sarcoma. As the former Chief of the Melanoma and Sarcoma Service (MSO) at Memorial Sloan-Kettering Cancer Center (MSKCC), he successfully brought together clinical researchers and basic scientists to establish one of the most successful clinical research programs in the Department of Medicine at MSKCC including many translational clinical trials with small molecule inhibitors and targeted immunologic agents. His efforts at Columbia similarly focused on precision medicine. This resulted in the recruitment of key leaders in the areas of early drug development and immunotherapy. As director of a laboratory in preclinical drug development, he developed NCI, FDA, and DOD grant-supported novel targeted agents for bench-top to bedside clinical translational research focusing on drugs that targeted the cell cycle ranging from CDK4 to Chk1. More recently, Schwartz has developed novel therapies for sarcoma and uveal melanoma which has resulted in a series of innovative translational clinical trials with inhibitors of MDM2, MEK, AKT, IGF-1R, mTOR, Notch, PARP, BRD4 and receptor tyrosine kinase inhibitors.
Best Practices for Uterine Sarcomas
ON-DEMAND